The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested protein identity is internally consistent: Mtmr12 in Rattus norvegicus corresponds to myotubularin-related protein 12, also called 3-phosphatase-associated protein (3-PAP) or inactive phosphatidylinositol 3-phosphatase 12. Its myotubularin-like inactive phosphatase and PH-like domain annotations agree with the established MTMR12 family architecture. No conflicting same-symbol protein was encountered.
The most defensible primary annotation is not “lipid phosphatase enzyme,” but noncatalytic phosphoinositide-phosphatase regulator/pseudophosphatase. MTMR12 binds active myotubularins—most importantly MTM1—and stabilizes and spatially organizes the complex. Consequently, it indirectly supports phosphatidylinositol-3-phosphate (PI3P) homeostasis and membrane organization. In skeletal muscle, mouse evidence places the MTM1–MTMR12 complex at the triad, where transverse tubules meet the sarcoplasmic reticulum. Loss of MTMR12 destabilizes MTM1 and produces abnormalities of triad architecture, myofiber organization, and motor function in zebrafish and mouse-derived cells. However, direct functional experiments on the precise rat protein A0A8I5ZMD5 remain very limited; most mechanistic conclusions are orthology-based.
| Claim | Evidence/model species | Evidence type | Confidence | Key limitation |
|---|---|---|---|---|
| A0A8I5ZMD5 is rat Mtmr12, encoding myotubularin-related protein 12/3-PAP; its MTMR12-like inactive PTP/myotubularin and PH-like domains agree with the established MTMR12 architecture. | Rat database annotation; human family/domain comparison | Sequence/domain annotation and orthology | High for identity; moderate for detailed architecture | The rat UniProt record is computationally annotated; the supplied record does not establish a rat protein-level experiment. Human MTMR12 schematics additionally identify PH-GRAM, inactive PTP/DSP, and coiled-coil regions (davies2012theptenand pages 28-31). |
| MTMR12 is a catalytically inactive pseudophosphatase and therefore has no demonstrated intrinsic phosphoinositide reaction or substrate specificity. | Rat inference from conserved annotation; human/vertebrate MTMR12 literature | Conserved catalytic-site degeneration plus family classification | High | General MTMR reactions—PI3P → PI and PI(3,5)P2 → PI5P—belong to active partners and must not be assigned directly to MTMR12 (gupta2013lossofcatalytically pages 2-4, davies2012theptenand pages 28-31). |
| MTMR12 directly binds MTM1 and helps maintain MTM1 protein abundance/stability. | Human recombinant proteins and patient myotubes; COS-1/COS-7 cells; mouse C2C12 cells and muscle; zebrafish | GST pull-down, co-immunoprecipitation, RNA knockdown, immunoblotting, rescue | High for conserved vertebrate function; moderate for rat specifically | No direct rat loss-of-function experiment was identified. Mtmr12 knockdown reduced MTM1 in three C2C12 experiments and three zebrafish clutches of 50–75 embryos each (gupta2013lossofcatalytically pages 2-4, gupta2013lossofcatalytically pages 9-10). |
| In skeletal muscle, the MTM1–MTMR12 complex localizes to triads, partly overlapping RyR1-positive sarcoplasmic-reticulum structures but not α-actinin-positive Z-lines. | Mouse tibialis-anterior muscle | Endogenous co-immunoprecipitation and confocal immunofluorescence | High in mouse; moderate by orthology for rat | Localization has not been demonstrated directly for A0A8I5ZMD5 in rat tissue (gupta2013lossofcatalytically pages 2-4, gupta2013lossofcatalytically media a8e7b663). |
| MTMR12 indirectly supports phosphoinositide homeostasis: its loss increases PI3P, plausibly through destabilization/dysregulation of active MTM1 and possibly other PI3P phosphatases. | Zebrafish; mechanistic support from mouse cells | Knockdown with lipid-level and protein-level analyses | Moderate | The evidence does not show MTMR12 catalyzing PI3P hydrolysis or define an MTMR12-specific substrate; double mtm1/mtmr12 depletion raised PI3P beyond mtm1 depletion alone (gupta2013lossofcatalytically pages 9-10). |
| Loss of mtmr12 causes a centronuclear-myopathy-like phenotype: impaired movement, central nuclei, myofiber hypotrophy, disorganized triads, and abnormal whorled membranes. | Zebrafish morphants; mouse C2C12 supportive evidence | Two morpholinos, histology/electron microscopy, birefringence and rescue assays | High in zebrafish; moderate for mammalian physiological relevance | Morpholino results are not equivalent to a stable rat knockout. Human MTM1 nearly restored birefringence, although rescued embryos remained about 75 ± 5.4% of control length (gupta2013lossofcatalytically pages 10-12, gupta2013lossofcatalytically pages 9-10, gupta2013lossofcatalytically pages 1-2). |
| Patient-specific MTMR12 variation may modify α1-antitrypsin-Z proteotoxic liver disease through autophagy/proteostasis, jointly with FAM134A variation. | Human family/cohorts and patient-derived iPSC hepatocyte-like cells | Genomic sequencing and cell-based variant testing (2024) | Preliminary/moderate | A putative polygenic modifier association, not proof that common MTMR12 dysfunction causes liver disease; applicability to rat A0A8I5ZMD5 or normal MTMR12 physiology is uncertain. DOI: 10.1097/HEP.0000000000000865. |
| MTMR12 currently has no validated direct therapeutic application or MTMR12-targeted clinical trial; complex stabilization and modulation of proteostasis remain research hypotheses. | Cross-species preclinical literature and clinical-target databases | Literature/trial landscape assessment | High for current status | XLMTM trials target the MTM1 disease pathway rather than MTMR12 itself. Open Targets associations largely derive from screening-level evidence and do not establish causal disease links (OpenTargets Search: -MTMR12, gupta2013lossofcatalytically pages 2-4). |
Table: Evidence supporting rat Mtmr12 annotation is separated from mouse, zebrafish, and human ortholog findings. The table highlights the strong conserved MTM1-regulatory model while exposing the lack of direct rat functional experiments and clinical validation.
MTMR12 belongs structurally to the protein-tyrosine-phosphatase/myotubularin superfamily but is classified as catalytically inactive, owing to degeneration of the catalytic site found in active family members. Therefore, no intrinsic reaction or substrate specificity should be assigned to rat MTMR12. In particular, the canonical active-myotubularin reactions—
are properties of active MTM/MTMR partners, not demonstrated reactions of MTMR12 itself. The literature consistently describes MTMR12/3-PAP as an inactive MTMR-family protein (gupta2013lossofcatalytically pages 2-4, gupta2013lossofcatalytically pages 1-2, davies2012theptenand pages 28-31).
This distinction is important for annotation: “inactive phosphatidylinositol 3-phosphatase” means a homologous pseudophosphatase, not an enzyme with weakly proven activity. Its retained phosphatase-like and lipid-binding architecture is instead interpreted as supporting molecular recognition, membrane targeting, and complex assembly.
The strongest experimentally supported function is formation of a complex with MTM1/myotubularin. A GST pull-down using recombinant human MTM1 and in-vitro-synthesized MTMR12 demonstrated direct protein–protein binding. Co-immunoprecipitation reproduced the association in COS-1 cells, and endogenous MTMR12 co-immunoprecipitated with MTM1 from mouse tibialis-anterior muscle (gupta2013lossofcatalytically pages 2-4, gupta2013lossofcatalytically media a8e7b663, gupta2013lossofcatalytically media c460b86b).
Loss-of-function evidence indicates that MTMR12 maintains MTM1 abundance or stability:
Collectively, these data support a model in which MTMR12 behaves as a noncatalytic partner or scaffold that stabilizes a functional MTM1 complex. MTMR12 can also associate with active MTMR2 and self-associate, suggesting that its regulatory role may extend beyond MTM1, although the physiological importance of these additional complexes is less well established (gupta2013lossofcatalytically pages 10-12, katharina2012structuralandfunctional pages 18-21).
MTM1 normally removes the D3 phosphate from PI3P and PI(3,5)P₂. These lipids regulate endosomal identity, membrane trafficking, autophagy-related membrane dynamics, and organelle homeostasis. MTMR12 can therefore affect phosphoinositide signaling indirectly by controlling the abundance, localization, or activity of active MTMR partners.
In zebrafish, absence of MTMR12 increased PI3P. Combined mtm1/mtmr12 depletion increased PI3P beyond that observed after mtm1 depletion alone, leading the investigators to suggest that MTMR12 may regulate additional PI3P phosphatases as well as MTM1 (gupta2013lossofcatalytically pages 9-10). This is meaningful pathway evidence, but it does not demonstrate direct PI3P hydrolysis by MTMR12 or establish an MTMR12-specific lipid substrate.
Earlier family-level studies proposed that inactive MTMR partners can increase catalytic activity, alter substrate preference, and relocalize active partners. For the MTM1–MTMR12 pair, however, the most robust in-vivo result is protein stabilization and localization, not a purified-enzyme demonstration that MTMR12 changes MTM1 substrate specificity (katharina2012structuralandfunctional pages 18-21, gupta2013lossofcatalytically pages 2-4).
The best localization evidence comes from mouse tibialis-anterior muscle. MTM1 and MTMR12 displayed matching striated distributions and colocalized at triads. MTMR12 partly overlapped RyR1, a sarcoplasmic-reticulum marker, but did not overlap α-actinin-positive Z-lines (gupta2013lossofcatalytically pages 2-4, gupta2013lossofcatalytically media a8e7b663).
The triad comprises a transverse tubule flanked by two terminal cisternae of the sarcoplasmic reticulum and is the core membrane junction for excitation–contraction coupling. Thus, MTMR12 is most plausibly a cytoplasmic, peripheral membrane-associated component of the MTM1 regulatory complex at specialized muscle membranes, rather than a transmembrane protein, extracellular protein, or secreted enzyme. Its PH-GRAM-like region likely contributes to lipid/membrane association, while protein-interaction regions support oligomerization; this architectural interpretation is inferred rather than experimentally mapped in the rat protein.
Zebrafish mtmr12 transcripts were reported in brain, eye, heart, and skeletal muscle during early development, with maternal transcripts at the one-cell stage and zygotic expression from approximately 8 hours post-fertilization through five days. Mtmr12 protein/expression also increased during differentiation of mouse C2C12 muscle cells (gupta2013lossofcatalytically pages 4-5). These observations suggest broad expression but do not establish that MTMR12 performs the same specialized function in every tissue.
The MTM1–MTMR12 complex is required for normal skeletal-muscle architecture. Zebrafish mtmr12 knockdown caused reduced muscle birefringence, impaired movement, centralized nuclei, myofiber hypotrophy, disorganized triads, and whorled membrane structures resembling X-linked myotubular/centronuclear myopathy (gupta2013lossofcatalytically pages 10-12, gupta2013lossofcatalytically pages 1-2).
Human MTM1 mRNA almost normalized muscle birefringence and improved ultrastructure in mtmr12-deficient zebrafish, supporting MTM1 destabilization as a major causal mechanism. Rescue was incomplete outside muscle architecture: treated embryos remained approximately 75±5.4% of control length. Conversely, human MTMR12 only partly rescued mtm1-deficient fish, improving relative length from 64±3.68% to 71±4.9% without significantly correcting disorganized triads (gupta2013lossofcatalytically pages 10-12, gupta2013lossofcatalytically pages 9-10). These asymmetric rescue results imply that active MTM1 supplies indispensable catalytic function, whereas MTMR12 chiefly supports MTM1 and may also have MTM1-independent roles.
Mtmr12 depletion in C2C12 cells caused abnormal accumulation of the intermediate-filament protein desmin and increased desmin abundance, while myogenin levels and the gross efficiency of myotube formation were not significantly altered. Myotube differentiation was assessed at days 2, 4, 6, and 9, with at least 100 cells per condition in two experiments (gupta2013lossofcatalytically pages 9-10). MTMR12 therefore appears more important for mature structural organization/protein homeostasis than for commitment to myogenic differentiation.
Because PI3P and PI(3,5)P₂ specify endosomal and lysosomal membrane states, altered MTM1-complex function is expected to affect vesicle trafficking and autophagy-associated membrane dynamics. This pathway placement is mechanistically reasonable and supported by increased PI3P following MTMR12 loss, but direct rat experiments tracking endosomal flux, autophagosome maturation, or lysosomal function were not found. A 2024 review emphasizes that MTMR-family effects on autophagy are highly member- and context-dependent, cautioning against transferring findings from MTMR6, MTMR8/9, or MTMR14 directly to MTMR12 (wang2024recentadvancesof pages 3-4, wang2024recentadvancesof pages 7-8).
A 2024 Hepatology study reported patient-specific variants in MTMR12 and the ER-phagy gene FAM134A as putative modifiers of hepatic disease in homozygous α1-antitrypsin deficiency. Investigators compared an unusually affected family—an index patient with liver failure and two homozygous siblings with little or no liver disease—with additional characterized cohorts, then tested variant effects in patient-derived iPSC hepatocyte-like cells. The variants altered the degradation kinetics of misfolded α1-antitrypsin Z, and the authors concluded that both variants were required to reproduce the protected sibling’s slower degradation phenotype. This supports a polygenic proteostasis-modifier model rather than monogenic disease causation by MTMR12. Publication: Tafaleng et al., online April 2024, DOI/URL: https://doi.org/10.1097/HEP.0000000000000865.
This result expands MTMR12 interest from muscle biology to ER proteotoxicity/autophagy. Nevertheless, it remains a human variant study in a particular disease context; it does not establish the normal molecular function of rat A0A8I5ZMD5, and the available retrieved text did not permit reliable extraction of additional numerical effect sizes.
Recent MTMR-family reviews continue to treat inactive MTMRs as regulatory partners whose physiological consequences depend on the associated active enzyme and cellular compartment. For MTMR12 specifically, the 2013 MTM1-stability study remains the central mechanistic primary source; the 2023–2024 literature has not yet supplied a rat knockout, a high-resolution MTMR12 structure, or a definitive purified-complex analysis of substrate specificity. The 2024 review concludes more generally that mechanistic understanding of MTMR-dependent regulation remains insufficient for therapeutic targeting (wang2024recentadvancesof pages 3-4, wang2024recentadvancesof pages 7-8).
MTMR12 itself is not established as a monogenic human disease gene in the way that MTM1 causes X-linked myotubular myopathy. Its strongest disease relevance is as a modifier or obligate functional partner:
No MTMR12-directed clinical trial or approved MTMR12-targeting drug was identified. Trials in X-linked myotubular myopathy concern the MTM1 disease pathway rather than MTMR12 itself. Accordingly, the present real-world application is primarily research use: interpreting MTM1-complex stability, modeling triad pathology, and investigating genetic modifiers of proteostasis.
A conservative annotation for rat A0A8I5ZMD5 is:
Catalytically inactive myotubularin-family pseudophosphatase and phosphoinositide-phosphatase-associated regulatory protein. Forms complexes with active myotubularins, particularly MTM1, supporting partner stability and localization. In skeletal muscle, ortholog evidence places the MTM1–MTMR12 complex at triad membranes, where it contributes to PI3P homeostasis, membrane organization, and normal myofiber/triad structure.
Suggested process terms, with evidence qualifiers, are:
The major limitation is the absence of direct experiments on rat A0A8I5ZMD5. Priority studies would include rat tissue proteomics and immunolocalization, CRISPR loss-of-function in rat myotubes or an in-vivo rat model, quantitative measurement of MTM1 half-life, lipidomics for PI3P/PI(3,5)P₂/PI5P, and reconstitution of purified rat MTM1–MTMR12 complexes. Structural work should determine how the inactive PTP domain, PH-GRAM-like region, and C-terminal interaction region bind MTM1 and membranes. Such experiments are required before assigning rat-specific localization outside muscle, autophagy directionality, or additional active-MTMR partners.
References
(davies2012theptenand pages 28-31): E. M. Davies, D. A. Sheffield, Priyanka Tibarewal, C. Fedele, C. Mitchell, and N. Leslie. The pten and myotubularin phosphoinositide 3-phosphatases: linking lipid signalling to human disease. Sub-cellular biochemistry, 58:281-336, 2012. URL: https://doi.org/10.1007/978-94-007-3012-0_8, doi:10.1007/978-94-007-3012-0_8. This article has 26 citations.
(gupta2013lossofcatalytically pages 2-4): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(gupta2013lossofcatalytically pages 9-10): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(gupta2013lossofcatalytically media a8e7b663): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(gupta2013lossofcatalytically pages 10-12): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(gupta2013lossofcatalytically pages 1-2): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(OpenTargets Search: -MTMR12): Open Targets Query (-MTMR12, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(gupta2013lossofcatalytically media c460b86b): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(gupta2013lossofcatalytically pages 12-13): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(katharina2012structuralandfunctional pages 18-21): Katharina Gegenschatz-Schmid. Structural and functional characterization of interactions of myotubularin-related proteins. ArXiv, 2012. URL: https://doi.org/10.3929/ethz-a-007313479, doi:10.3929/ethz-a-007313479. This article has 0 citations.
(gupta2013lossofcatalytically pages 4-5): Vandana A. Gupta, Karim Hnia, Laura L. Smith, Stacey R. Gundry, Jessica E. McIntire, Junko Shimazu, Jessica R. Bass, Ethan A. Talbot, Leonela Amoasii, Nathaniel E. Goldman, Jocelyn Laporte, and Alan H. Beggs. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. Jun 2013. URL: https://doi.org/10.1371/journal.pgen.1003583, doi:10.1371/journal.pgen.1003583. This article has 41 citations and is from a domain leading peer-reviewed journal.
(wang2024recentadvancesof pages 3-4): Jia Wang, Wei Guo, Qiang Wang, Yongjian Yang, and Xiongshan Sun. Recent advances of myotubularin-related (mtmr) protein family in cardiovascular diseases. Frontiers in Cardiovascular Medicine, Mar 2024. URL: https://doi.org/10.3389/fcvm.2024.1364604, doi:10.3389/fcvm.2024.1364604. This article has 16 citations and is from a peer-reviewed journal.
(wang2024recentadvancesof pages 7-8): Jia Wang, Wei Guo, Qiang Wang, Yongjian Yang, and Xiongshan Sun. Recent advances of myotubularin-related (mtmr) protein family in cardiovascular diseases. Frontiers in Cardiovascular Medicine, Mar 2024. URL: https://doi.org/10.3389/fcvm.2024.1364604, doi:10.3389/fcvm.2024.1364604. This article has 16 citations and is from a peer-reviewed journal.